Valbiotis - Increased Momentum in the Clinical Newsflow for Major Indications: Results Expected in 2022 for Prediabetes, Hypercholesterolemia and High Blood Pressure
Valbiotis (Paris:ALVAL) (FR0013254851 – ALVAL, PEA/SME eligible), a Research and Development company committed to scientific innovation for preventing and combating metabolic and cardiovascular diseases, updates its calendar, which will gain momentum in 2022 with a number of clinical study results expected during the year concerning the prevention of metabolic and cardiovascular diseases. Clinical results regarding three active substances in the portfolio will become available and will be key for the launch of these substances on the prediabetes, hypercholesterolemia and high blood pressure markets. The Company is fully able to finance this market plan today.
Sébastien PELTIER, CEO of Valbiotis, commented: “After a year of substantive work in 2021, dedicated in particular to moving the clinical plans for our three initial active substances forward, 2022 should provide significant clinical results for three key indications: prediabetes, hypercholesterolemia and high blood pressure. These clinical results are critical: they must demonstrate that our innovative active substances are effective for patients and meet the goal of preventing metabolic and cardiovascular diseases in their earliest stages. These results must also allow us to rapidly reach a new milestone in our development: converting our scientific expertise into a marketable reality. I hope that, by reaching these objectives, we will meet the expectations of all our stakeholders - patients, healthcare professionals, partners and investors - and confirm Valbiotis’ positioning as a leader in disease prevention, in line with public healthcare policies.”
The clinical study results calendar announced for 2022 complies with the development plans adopted for Valbiotis’ active substances. These plans were designed to support a highly differentiating marketing positioning on the prevention market, based on clinical evidence and proprietary health claims, with the goal being a rapid market launch.
Murielle CAZAUBIEL, Member of the Board of Directors and Director of Medical, Regulatory and Industrial Affairs at Valbiotis, stated: “Decisive clinical advances should be achieved in 2022 on three active substances in our portfolio, the first major high point being in the field of hypercholesterolemia with TOTUM•070. This will be followed by initial clinical bioavailability and mode of action data for TOTUM•854, which targets management of arterial hypertension - here again, the need is great - before the highly anticipated TOTUM•63 results at the end of the year.
I strongly believe that our efforts will be rewarded with solid clinical results, which are both the DNA of our R&D and at the heart of our strategy to access the prevention market for metabolic and cardiovascular diseases.”
Details on the clinical results expected in 2022 are as follows:
Decisive clinical results for TOTUM•63 to combat prediabetes in 4th quarter of 2022
The results of the pivotal Phase II/III REVERSE-IT study on TOTUM•63 should be available by the end of 20222. This major international multicenter study, conducted on 600 hyperglycemic volunteers, should confirm the Phase II results obtained in 2019 in a similar population.
In addition, an exploratory study on the mode of action will be conducted by the Institute of Nutrition and Functional Foods (INAF) of Laval University in Quebec. This study will include 20 volunteers and will explore numerous mechanistic parameters of the pathophysiology of prediabetes and type 2 diabetes (press release of June 28, 2021).
The TOTUM•63 studies are conducted as part of a global strategic partnership with Nestlé Health Science and will be the subject of milestone payments, dedicated in particular to their financing.
Efficacy and mode of action results for TOTUM•070 in combating hypercholesterolemia in 2nd quarter of 2022
The results of the Phase II HEART study will be announced in the second quarter of 2022. This multicenter study should demonstrate the efficacy of TOTUM•070 in reducing LDL-cholesterol levels compared to a placebo in 120 volunteers presenting untreated mild to moderate hypercholesterolemia. These results will be decisive for the market launch of TOTUM•070, an innovative active substance that is 100% plant-based, with no phytosterol or red yeast rice content, and for its positioning as a leading non-drug option to combat LDL-cholesterol.
At the same time, an open-label study on the bioavailability and mode of action of TOTUM•070, conducted on 10 volunteers, will also provide results in the second quarter of 2022. It combines a clinical evaluation, a bioavailability study, the identification of metabolites, and in vitro mechanistic explorations on human cell lines.
Bioavailability and mode of action results for TOTUM•854 in the management of arterial hypertension in 4th quarter of 2022
The results of the open-label study on the bioavailability and mode of action of TOTUM•854, conducted on 10 volunteers, will be available in the fourth quarter of 2022. Like the TOTUM•070 study, this study combines a clinical evaluation, a bioavailability study, the identification of metabolites and in vitro mechanistic explorations on human cell lines involved in regulating blood pressure.
TOTUM•854 is an active substance based on five plant extracts, designed to reduce blood pressure. Its clinical development includes two Phase II/III studies, whose protocols were submitted in December 2021 (press release of December 1, 2021). They should demonstrate the efficacy of TOTUM•854 in reducing systolic blood pressure, compared to a placebo, in a population of volunteers presenting untreated mild to moderately high blood pressure.
In addition to these three active substances in their clinical phase, whose results will be available in 2022, Valbiotis is working on the development of TOTUM•448, an active substance to combat metabolic liver diseases (NAFL and NASH).
TOTUM•448: an updated plan to combat metabolic liver diseases (NAFL and NASH)
TOTUM•448, the fourth active substance in Valbiotis’ portfolio, is being developed to address unmet needs in the treatment of metabolic liver diseases: non-alcoholic fatty liver disease and non-alcoholic steatohepatitis (NAFL and NASH). The development plan has been updated to better meet the challenges of these emerging pathologies for which effective preventive and therapeutic strategies have yet to be identified. This plan will be based on an innovatively designed study, conducted in “real life” in healthcare centers, directly involving patient management. Combined with clinical studies on mode of action, this work, conducted very close to the field, will allow for TOTUM•448 to be optimally positioned for the management of NAFL and NASH. Details on this development plan will be announced at a future time.
Valbiotis is a Research & Development company committed to scientific innovation for preventing and combating metabolic diseases in response to unmet medical needs.
Valbiotis has adopted an innovative approach, aiming to revolutionize healthcare by developing a new class of health nutrition products designed to reduce the risk of major metabolic diseases, relying on a multi-target strategy enabled by the use of plant-based terrestrial and marine resources.
Its products are intended to be licensed to players in the health sector.
Created at the beginning of 2014 in La Rochelle, the Company has forged numerous partnerships with leading academic centers. The Company has established three sites in France – Périgny, La Rochelle (17) and Riom (63) – and a subsidiary in Quebec City (Canada).
Valbiotis is a member of the "BPI Excellence" network and has been recognized as an "Innovative Company" by the BPI label. Valbiotis has also been awarded "Young Innovative Company" status and has received major financial support from the European Union for its research programs via the European Regional Development Fund (ERDF). Valbiotis is a PEA-SME eligible company.
For more information about Valbiotis, please visit: www.valbiotis.com
ISIN code: FR0013254851
Ticker symbol: ALVAL
EnterNext© PEA-PME 150
This press release contains forward-looking statements about Valbiotis’ objectives. Valbiotis considers that these projections are based on rational hypotheses and the information available to Valbiotis at the present time. However, in no way does this constitute a guarantee of future performance, and these projections may be affected by changes in economic conditions and financial markets, as well as certain risks and uncertainties, including those described in the Valbiotis Universal Registration Document approved by the French Financial Markets Regulator (AMF) on July 27, 2021 (application number R 21-039). This document is available on the Company’s website (www.valbiotis.com).
This press release and the information it contains do not constitute an offer to sell or subscribe, or a solicitation to purchase or subscribe to Valbiotis’ shares or financial securities in any country.
1Institute of Nutrition and Functional Foods (INAF)
2Initially planned for mid-2022
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Corporate communication / Valbiotis
Carole Rocher / Marc Delaunay
+33 5 46 28 62 58
Financial communication / Actifin
+33 1 56 88 11 14
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Megaport Announces Expansion to Mexico, Bringing Network as a Service (NaaS) and Direct Access to Leading Cloud Services to KIO Networks17.1.2022 00:00:00 EET | Press release
Megaport Limited (ASX: MP1) ("Megaport"), a global leading Network as a Service (NaaS) provider, today announces plans to expand services to Mexico via a partnership with KIO Networks, the country’s largest data centre provider. Cloud connectivity services to Microsoft Azure and Google Cloud are expected to be available in March 2022 to local enterprises via on-ramps from KIO Networks’ data centres in Mexico City and Queretaro, subject to approvals. Customers of KIO Networks in Mexico will be able to access Megaport’s leading ecosystem of more than 700 enabled data centres worldwide and over 360 service providers, including 230+ cloud on-ramps from the world's leading clouds such as AWS, Google Cloud, Microsoft Azure, IBM Cloud, and Oracle Cloud. Businesses in Mexico can seamlessly and directly connect to cloud and IT services on a global level without the need to manage complex network infrastructure. According to IDC, Mexico is the second largest market in Latin America when it comes
Hanshow Makes US Market Debut at 2022 NRF Big Show14.1.2022 23:00:00 EET | Press release
Global digital retail solutions provider Hanshow is making its US market debut this week at the annual NRF Big Show in New York where it’s showcasing a series of new products, announcements, and partnerships. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220114005005/en/ 2022 NRF venue, the Javits Center in New York (Photo: Business Wire) Hanshow was founded ten years ago with an initial focus on just electronic shelf labels (ESL). After often triple digit annual growth, expansion across Europe, Asia Pacific and 50 countries around the world, the company is now bringing its impressive suite of digital retail solutions to the world’s largest retail market. Now after a decade of tested results with some of the world’s leading retailers including Auchan, Ahold Delhaize, Yamada Denki and many more, Hanshow believes it has the solutions US retailers need to evolve and thrive in this period of uncertainty for the retail. The comp
CI&T Acquires Somo to Accelerate Its Growth in EMEA14.1.2022 20:27:00 EET | Press release
CI&T (NYSE: CINT), a global digital specialist, announces today the execution of a sale and purchase agreement to acquire Somo Global Ltd ("Somo"), an award-winning digital product agency headquartered in the UK, to accelerate its growth in EMEA, the second-largest market for digital services. In this strategic move, Somo will join CI&T’s EMEA operation and enhance its growing operations by adding almost 300 digital specialists with deep expertise in digital products, working with some of the world’s largest brands including Audi, Vanguard, Vodafone and Virgin Media, among others. Somo is one of the UK’s leading independent digital product agencies, recognized by Econsultancy's prestigious Top 100 ranking (2019). With offices in the UK, USA and Colombia, Somo delivers digital ambitions at pace and scale across several verticals including automotive, financial services, utilities and telecom. Its strong leadership team brings a proven track record of delivering business performance, win
Alpha Blue Ocean Announces the Launch of WiSeSat by WiSeKey on the Space X’s Transporter 3 mission14.1.2022 18:00:00 EET | Press release
Alpha Blue Ocean, the family office founded by Pierre Vannineuse and financial partner of WISeKey (Tickers: SW: WIHN and US: WKEY), announces the new technological breakthrough of the Swiss group led by Carlos Creus Moreira. On January 13, 2022, WISeKey launched the audacious project to generate the first NFT from space... On January 13, 2021, WISeKey launched its first WISeSat pico satellite via SpaceX's (*) Falcon 9 rocket as part of the Transporter 3 mission to generate the first NFT from space. The NFT will be captured by the WISeSat satellite station in La Linea in south of Spain and minted on WISe.ART NFT Marketplace. Pierre Vannineuse founder and CIO of Alpha Blue Ocean said “Alpha Blue Ocean would like to praise this technological hardware and software achievement by WISeKey's teams. It will allow the NFT ecosystem to evolve towards a truly global constellation by generating the first NFT from space! We are over the moon to have participated in the financing of WISeKey in order
pmdtechnologies Announces Second Generation 3D ToF Depth-Sensing Development Kit14.1.2022 17:00:00 EET | Press release
Today, pmdtechnologies ag is announcing the next generation of its 3D Time-of-Flight Development Kit, the “flexx2”. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220112005533/en/ Next-generation 3D Time-of-Flight Development Kit for prototyping, research, and mass production. (Graphic: Business Wire) Working in Partnership with Emcraft Systems, a California based provider of hardware and software solutions for embedded applications, the flexx2 has been upgraded from the market-leading “PicoFlexx” to deliver even better depth-sensing performance with 38,000 3D pixels and a 56 x 44 degree Field-of-View, all in the size of a pack of chewing gum at 72.1mm x 19.2mm x 10.2mm. The VCSEL emitter has been upgraded from 850-nanometer to 940-nanometer wavelength to further increase sunlight robustness and outdoor performance. Additionally the USB-A port was replaced by a more robust USB 3.0 type C port. Multiple new built-in user mode
Rubicon Advises Elgin Energy on the Sale of the UK’s Largest Portfolio of Solar PV Projects14.1.2022 14:50:00 EET | Press release
Rubicon Capital Advisors (“Rubicon”), one of the world’s leading investment banking firms focused on the broader infrastructure, energy and digital sectors, announced its role as exclusive sell-side financial advisor to Elgin Energy Holdings (“Elgin”) in reaching completion on the 100% sale of a 519 MW portfolio of solar PV projects and 70 MW of co-located energy storage capacity (the “Portfolio”) to ScottishPower Renewables (UK) Limited (“Scottish Power”), a wholly-owned subsidiary of global utility Iberdrola Group. The portfolio sale marks the UK’s largest solar PV transaction to date, consisting of 12 projects at the pre-construction stage located across England, Wales and Scotland, with a combined capacity of 519MW. The portfolio also includes a co-located 70MW battery solution that is at an advanced stage of development. “We are delighted to have reached this significant milestone and partnered with Iberdrola / ScottishPower Renewables on this portfolio. We will continue to develo
Florida’s Apis Cor Set to Become 1st 3D Printed Homes Tech Firm to Offer Shares to Public14.1.2022 13:00:00 EET | Press release
Apis Cor, an additive manufacturing firm incorporated in the US State of Florida, has been qualified by the US Securities and Exchange Commission to offer shares to the public – the first company of its kind to do so. The development comes as additive manufacturing (also known as 3D printing) is poised to see exponential growth in the short term, as construction firms begin to adopt 3D-printing technologies on a global scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220112005677/en/ With the aim of providing affordable housing for the 21st century, Apis Cor vows to reduce home-construction times from three months to a mere five days. (Photo: Business Wire) “This is a truly historic moment,” Apis Cor CEO Anna Cheniuntai says. “Now everyone – even small individual investors – can become part of this exciting new field, which is set to revolutionize the construction industry in the months and years ahead.” Construction Se
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom